title: Evaluation of cefuroxime axetil and cefadroxil suspensions for treatment of pediatric skin infections.
abstract: A randomized, single-blind, multicenter study was conducted to evaluate the safety and efficacy of cefuroxime axetil and cefadroxil suspensions for the treatment of skin or skin structure infections in 287 children. Each drug was given at a dosage of 30 mg/kg of body weight per day in two divided doses. Staphylococcus aureus and Streptococcus pyogenes, or a combination of the two, were the primary pathogens isolated from infected skin lesions. A satisfactory bacteriological response (cure or presumed cure) was obtained in 97.1 and 94.3% of children in the cefuroxime axetil and cefadroxil groups, respectively (P greater than 0.05). Satisfactory clinical responses (cure or improvement) were more likely to occur in cefuroxime axetil recipients than in cefadroxil recipients (97.8 versus 90.3%; P less than 0.05). Both regimens were equally well tolerated, with adverse events occurring in 7.9 and 6.1% of cefuroxime axetil and cefadroxil recipients, respectively. There were more patients who refused to take cefuroxime axetil (7 of 189) than there were who refused to take cefadroxil (0 of 98), but the difference was not statistically significant (P = 0.1). In this study, cefuroxime axetil was at least as effective as cefadroxil in resolving skin and skin structure infections in children.
authors.affiliation: Arkansas Children's Hospital, Little Rock 72202.
authors.forename: R F
authors.initials: RF
authors.lastname: Jacobs
authors.forename: W D
authors.initials: WD
authors.lastname: Brown
authors.forename: S
authors.initials: S
authors.lastname: Chartrand
authors.forename: P
authors.initials: P
authors.lastname: Darden
authors.forename: M A
authors.initials: MA
authors.lastname: Drehobl
authors.forename: R
authors.initials: R
authors.lastname: Yetman
authors.forename: M J
authors.initials: MJ
authors.lastname: Ossi
mesh_terms: D002434:Cefadroxil / Q000008:administration & dosage / Q000627:therapeutic use*; D002444:Cefuroxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011355:Prodrugs; D016037:Single-Blind Method; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000382:microbiology; D013535:Suspensions
chemical_list: D011355:Prodrugs; D013535:Suspensions; D002434:Cefadroxil; D002444:Cefuroxime; C040738:cefuroxime axetil